secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-08-04T21:20:45+00:00
Accession:  0001087294-26-000058
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss
--------------------------------------------------------------------------------

- Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.
- Paid special cash dividend of $1.50 per share on July 31, 2026 to shareholders of record July 23.
- Q2 2026 loss from continuing operations $3.1M; net loss $4.1M; cash $4M; retired $5.2M credit line.
- Phase 2 ifetroban in DMD showed biomarker evidence of cardiac protection; cancer metastasis study met safety endpoint.
- Metastatic recurrence 17% ifetroban vs 50% placebo (p=0.09); deaths from metastasis 0% vs 30% (p=0.037).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/0001087294-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/cpix-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer